IBRX is trading 5.3% down at $8.44 as investors lock in profits following a period of significant gains.
- The stock's recent rally was fueled by optimism surrounding its ANKTIVA bladder cancer therapy and regulatory milestones achieved earlier in 2026.
- Today's decline appears to be driven by short-term volatility and a weak broader market rather than fresh company-specific news or analyst downgrades.
- Traders are likely reacting to elevated forecasts and prior strong-buy sentiment as the stock consolidates after its recent upward move.